Ardelyx Reports Q2 2025 Earnings: Revenue Up 33% to $97.7M, Raises IBSRELA Revenue Expectations to $250-$260M

Ardelyx reported Q2 2025 financial performance with $97.7 million in total revenue, a 33% increase YoY. IBSRELA generated $65 million in net sales revenue, an 84% YoY increase, and XPHOZAH generated $25 million. The company ended the quarter with a net loss of $19.1 million and a cash position of $238.5 million. Ardelyx raised its 2025 revenue expectations for IBSRELA to $250-$260 million and made strategic moves to strengthen its financial position.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company, reported its second-quarter 2025 financial results, showcasing robust commercial performance and strategic moves to strengthen its financial position. The company reported total revenue of $97.7 million, a 33% increase year-over-year (YoY), driven by significant growth in its commercial products, IBSRELA and XPHOZAH.

IBSRELA, a treatment for Irritable Bowel Syndrome with Constipation (IBS-C), generated net sales revenue of $65.0 million, an 84% YoY increase. This performance reflects the highest demand quarter for IBSRELA, with record highs in new and refill prescriptions and new and repeat writers. The company has raised its 2025 revenue expectations for IBSRELA to $250-$260 million. XPHOZAH, a treatment for chronic kidney disease (CKD) on dialysis, generated net sales revenue of $25.0 million, driven by growing demand among prescribing healthcare providers. This quarter saw a 7% increase in XPHOZAH net sales revenue compared to the first quarter of 2025.

Despite the strong revenue growth, Ardelyx reported a net loss of $19.1 million for the second quarter of 2025, primarily due to increased commercialization and administrative investments to support net sales growth. The company ended the quarter with a cash position of $238.5 million, reflecting a net cash outflow of $48.7 million under its term loan with SLR Investment Corp.

The company has made strategic moves to bolster its financial position, including an amendment to its loan agreement with SLR Investment Corp., which allows Ardelyx to draw an additional $100 million in debt. Additionally, Ardelyx appointed Mike Kelliher as Chief Business Officer and James P. Brady as Chief Human Resources Officer.

Ardelyx will host a conference call on August 4, 2025, at 4:30 PM ET to discuss its Q2 2025 financial results and business update. The company's investor relations page provides more information about the call and a webcast.

References:
[1] https://finance.yahoo.com/news/ardelyx-reports-second-quarter-2025-200100458.html